Tags : Updated

Pharma

Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial

Shots: The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into 3 cohorts: Cohort A (N=107, FGFR2 fusions or rearrangements), Cohort B (N=20, other FGF/FGFR genetic alterations) or Cohort C (N=18, no FGF/FGFR genetic alterations)   […]Read More

Biosimilars

Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines

The new updated guidelines are being built on previous recommendations based on best practices for imaging, managing biologic and biosimilars usage in patients, and providing information on new medication The guidelines included 20 clinical questions based on pharmacological treatment indicated in 2015 guidelines and 26 new question on the pharmacological treatment treat-to-target strategy, and use […]Read More

Pharma

Gilead Reports Updated Results of Descovy in P-III DISCOVER Study

Shots: The P-III DISCOVER study involves assessing of Descovy (emtricitabine, 200 mg/tenofovir alafenamide, 25 mg, qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender female with HIV PrEP The P-III DISCOVER study results: met its 1EPs of non-inferiority, reduction in time to achieve EC90 of tenofovir diphosphate (TFV-DP) in […]Read More

Pharma

Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062

Shots: The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma The P-III KEYNOTE-062 results: as monothx. met its 1EPs, noninferior to CT; as a combination therapy, no superiority […]Read More